Merck-Moderna mRNA Cancer Therapy Hits Phase 3 Endpoints in Melanoma
MRK sits 74% above its 52-week low of $77.58.
Summary
The Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival in completely resected stage IIB-IV melanoma. This is the first positive Phase 3 readout for an individualized neoantigen therapy and for an mRNA-based cancer therapy, and the first Phase 3 study to show a clinically meaningful improvement over KEYTRUDA alone in the adjuvant melanoma setting. The trial enrolled 1,137 patients randomized 2:1 to the combination versus KEYTRUDA alone. Safety was consistent with prior studies, with no new signals. Data will be presented at an upcoming medical meeting and shared with regulators. For Moderna, this validates the mRNA platform beyond vaccines; for Merck, it extends the KEYTRUDA franchise into a new adjuvant paradigm. Overall survival data remain immature, and regulatory submission timing is not yet specified. Moderna stock surged 70% and Merck rose 6% following the news.
At the time of this announcement, MRK was trading at $135.24 on NYSE in the Life Sciences sector, with a market capitalization of approximately $333.5B. The 52-week trading range was $77.58 to $137.98. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.